Literature DB >> 12675138

Beta-amyloid and cholinergic neurons.

Vladimír Dolezal1, Jana Kasparová.   

Abstract

It is generally accepted that the crucial events in the pathogeny of Alzheimer's disease (AD) are the increased accumulation of amyloidogenic peptides derived from amyloid precursor protein and the harmful actions of these peptides on neurons, which bring about neurodegeneration. The enhanced beta-amyloid accumulation is known to be caused by mutations of specific genes in patients who suffer from the familial (hereditary) form of AD but who represent just a minor group within the total population of AD patients. The reasons for beta-amyloid accumulation are not known in the much larger group of patients with the sporadic form of the disease. A biochemical feature common to either form of the disease is the preferential atrophy and degeneration of cholinergic neurons, which is probably responsible for much of the cognitive decline characteristic of the disease. We present an overview of recent investigations on the interactions between beta-amyloid and cholinergic neurons.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675138     DOI: 10.1023/a:1022865121743

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  140 in total

1.  Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases.

Authors:  K Shirotani; S Tsubuki; N Iwata; Y Takaki; W Harigaya; K Maruyama; S Kiryu-Seo; H Kiyama; H Iwata; T Tomita; T Iwatsubo; T C Saido
Journal:  J Biol Chem       Date:  2001-03-06       Impact factor: 5.157

2.  Elevated intracellular calcium concentration increases secretory processing of the amyloid precursor protein by a tyrosine phosphorylation-dependent mechanism.

Authors:  M A Petryniak; R J Wurtman; B E Slack
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

Review 3.  Protein oxidation in aging, disease, and oxidative stress.

Authors:  B S Berlett; E R Stadtman
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

Review 4.  Copernicus revisited: amyloid beta in Alzheimer's disease.

Authors:  J Joseph; B Shukitt-Hale; N A Denisova; A Martin; G Perry; M A Smith
Journal:  Neurobiol Aging       Date:  2001 Jan-Feb       Impact factor: 4.673

5.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

6.  Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system.

Authors:  L Lin; C J LeBlanc; T W Deacon; O Isacson
Journal:  Neuroreport       Date:  1998-02-16       Impact factor: 1.837

Review 7.  The cholinergic neuronal phenotype in Alzheimer's disease.

Authors:  J K Blusztajn; B Berse
Journal:  Metab Brain Dis       Date:  2000-03       Impact factor: 3.584

8.  Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes.

Authors:  D Hernandez; K Sugaya; T Qu; E McGowan; K Duff; M McKinney
Journal:  Neuroreport       Date:  2001-05-25       Impact factor: 1.837

9.  Antibody-regulated neurotoxic function of cell-surface beta-amyloid precursor protein.

Authors:  H Sudo; H Jiang; T Yasukawa; Y Hashimoto; T Niikura; M Kawasumi; S Matsuda; Y Takeuchi; S Aiso; M Matsuoka; Y Murayama; I Nishimoto
Journal:  Mol Cell Neurosci       Date:  2000-12       Impact factor: 4.314

10.  Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain.

Authors:  M Hoshi; A Takashima; K Noguchi; M Murayama; M Sato; S Kondo; Y Saitoh; K Ishiguro; T Hoshino; K Imahori
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

View more
  7 in total

1.  The increase of choline acetyltransferase activity by docosahexaenoic acid in NG108-15 cells grown in serum-free medium is independent of its effect on cell growth.

Authors:  Eva Machová; Barbora Málková; Vera Lisá; Jana Nováková; Vladimír Dolezal
Journal:  Neurochem Res       Date:  2006-10       Impact factor: 3.996

Review 2.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

Review 3.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.

Authors:  Satyabrata Kar; Stephen P M Slowikowski; David Westaway; Howard T J Mount
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

4.  A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides.

Authors:  Qiang Liu; Yao Huang; Fenqin Xue; Alain Simard; Jamie DeChon; Guohui Li; Jianliang Zhang; Linda Lucero; Min Wang; Michael Sierks; Gang Hu; Yongchang Chang; Ronald J Lukas; Jie Wu
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

5.  Protective Effects of Fibroblast Growth Factor 21 Against Amyloid-Beta1-42-Induced Toxicity in SH-SY5Y Cells.

Authors:  Mona Amiri; Nady Braidy; Malihe Aminzadeh
Journal:  Neurotox Res       Date:  2018-06-05       Impact factor: 3.911

6.  An olfactory 'stress test' may detect preclinical Alzheimer's disease.

Authors:  Peter W Schofield; Houman Ebrahimi; Alison L Jones; Grant A Bateman; Sonya R Murray
Journal:  BMC Neurol       Date:  2012-05-02       Impact factor: 2.474

7.  Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease.

Authors:  Jeffrey N Motter; Xinhua Liu; Min Qian; Hannah R Cohen; Davangere P Devanand
Journal:  Alzheimers Dement (Amst)       Date:  2021-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.